COMMUNIQUÉS West-GlobeNewswire

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third quarter of 2025 [...]
Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results
14/05/2025
FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial [...]
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
14/05/2025
Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experience Announced selection of IL15-superagonist as first payload to be delivered into tumors with [...]
Eton Pharmaceuticals to Participate at Upcoming Investor Conferences
14/05/2025
DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year
14/05/2025
Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; [...]
Jasper Therapeutics to Present at Upcoming Investor Conferences
14/05/2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
14/05/2025
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company’s approach to corporate responsibility. The report [...]
SS Innovations Reports First Quarter 2025 Financial Results
14/05/2025
Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3 FORT LAUDERDALE, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- SS [...]
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
14/05/2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of [...]
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
14/05/2025
Correction: Time of BofA Conference SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that [...]
Precipio Announces its Q1-2025 Financial Results
14/05/2025
Conference call to follow tomorrow, May 15 at 5 PM EST NEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , filed its 10-Q report today. The following [...]
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
14/05/2025
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption (IDE) [...]
Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results
14/05/2025
CARLSBAD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced [...]
RAMSAY SANTE : Résultats intermédiaires au 31 mars 2025
14/05/2025
COMMUNIQUÉ DE PRESSE Paris, le 14 mai 2025 Résultats intermédiaires au 31 mars 2025 Croissance de l'activité et contrôle des coûts compensent une tarification défavorable Le chiffre d’affaires non audité du groupe pour [...]
RAMSAY SANTE : Interim results at the end of March 2025
14/05/2025
PRESS RELEASE Paris, 14 th May 2025 Interim results at the end of March 2025 Activity growth and cost control compensate pricing headwinds Unaudited group revenue for the nine months period ending 31 March 2025 [...]
Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
14/05/2025
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 14 May 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the [...]
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
14/05/2025
Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML Oral presentation at EHA will include updated data at the 40 mg and 80 mg dose levels [...]
Compte-rendu de l'Assemblée générale du 14 mai 2025 et précision sur l'avancement du Plan de renforcement de la structure financière
14/05/2025
Communiqué de presse Compte rendu de l’Assemblée générale du 14 mai 2025 - précision sur l’avancement du plan de renforcement de la structure financière Paris, le 14 mai 2025 – L’Assemblée générale annuelle des [...]
Minutes of the General Meeting of 14 May 2025 and additional information on the plan to reinforce the financial position
14/05/2025
Press release 14 May 2025 Minutes of the General Meeting of 14 May 2025 - additional information on the progress of the plan to reinforce its financial structure Paris, 14 May 2025 – The Annual General Meeting of [...]

Pages